Merck Raises 2026 Sales to $67.3B, but EPS Slashes to $2.66-$2.76-Why the Split Matters Now

Merck's 2026 guidance split comes down to sales growth and deal charges

Merck delivered an unusual mix of signals: sales guidance moved higher while profit guidance fell sharply. The company now expects 2026 adjusted EPS of $2.66 to $2.76, down from $5.04 to $5.16. At the same time, it raised its full-year sales outlook to $66.3 billion to $67.3 billion from $65.8 billion to $67.0 billion.

That divergence is the story. Investors need to determine whether this is mainly a temporary earnings hit from the Terns acquisition, or an early sign that Merck's profit cushion is narrowing faster than revenue growth can offset it.

The core business still looked healthy

The quarter itself did not read like a demand slowdown. Merck reported $16.61 billion in Q2 sales, including $8.4 billion from Keytruda and Keytruda QLEX, $588 million from Winrevair, and $1.8 billion from Animal Health. That suggests the drop in EPS guidance was not caused by an obvious collapse in underlying demand.

Why EPS weakened without an obvious business break

The cleaner explanation is mechanical. Merck said the updated profit outlook includes a one-time charge of $2.31 a share tied to the Terns acquisition, plus about 12 cents a share from financing the deal and advancing Terns's blood-cancer asset. In other words, the lower EPS view may reflect upfront acquisition accounting as much as it reflects weaker operations.

That is why the next step matters. Investors are really asking whether higher sales revisions and lower EPS revisions can reconcile before Keytruda faces 2028 patent protection loss. If they do, the market may be able to look through a temporary earnings dip. If not, the story becomes less about accounting noise and more about a lasting margin reset.

Merck is paying for TERN-701 because it needs pipeline depth before the Keytruda cliff

What Merck is actually buying

The headline number is easy to focus on, but the business logic matters more. Merck is paying $53.00 per share in cash, for an approximate equity value of $6.7 billion, or roughly $5.7 billion net of acquired cash. This is not a cheap biotech snapshot deal; Merck is paying up for an asset with clinical data, a defined patient population, and a clear development path.

TERN-701 is an oral allosteric BCR::ABL1 tyrosine kinase inhibitor in the Phase I/II CARDINAL trial for patients with chronic myeloid leukemia, including people whose disease has not responded well to prior therapy. For a company planning beyond Keytruda, that is the kind of early-stage asset pipeline investors expect a large pharma buyer to add before the data are fully proven.

Why TERN-701 deserves attention

The scientific hook is straightforward. TERN-701 is designed as an allosteric BCR::ABL1 inhibitor, giving it a different mechanism from existing treatments. It is being studied in heavily pretreated patients, a group where options remain limited, and early results have shown promising molecular response rates and a favorable safety profile. Analysts already describe the asset as a potential best-in-class candidate in hematology, and some see upside for a future multibillion-dollar drug.

There is also a plausible commercial gap to fill. Merck has said a meaningful share of patients on current tyrosine kinase inhibitors may need to switch therapy over time, and not everyone achieves a durable response. If TERN-701 can help address that unmet need, the acquisition would do more than add one asset; it would deepen Merck's presence in hematology at a time when it needs more post-Keytruda growth lanes.

The debate, though, is still balanced. Bulls will say Merck is using its scale to buy time and optionality before the 2028 cliff. Bears will say a roughly $5.7 billion net price for a pre-revenue oncology asset is still aggressive, and that premium would be hard to justify if the clinical program stumbles.

What investors should watch on the August earnings call

After the acquisition, the more useful question is not whether the headline EPS cut looks dramatic. It is whether this is a rough quarter for earnings caused by deal charges, or the start of a more sustained profitability problem.

The next decision point is close

Merck's investor calendar points to the August 3 Q2 2026 earnings call, the day before the August 4, 2026 results release. That call matters because investors need management to separate accounting friction from operating trends as clearly as possible.

The setup is still shaped by the Terns charges. Merck says the new profit outlook includes a one-time charge of $2.31 a share, plus about 12 cents a share from financing the deal and advancing Terns's blood-cancer asset. If those costs are mostly deal-related, earnings can recover even while the business keeps growing. If not, investors may need to revalue Merck on lower-margin assumptions rather than treat this as a one-quarter distortion.

What has to hold up

The bull case rests on portfolio diversification. Management said second-quarter growth was supported by newer drugs strengthening the pipeline, including Winrevair and Lipfendra, while broader launch momentum also contributed.

Investors should listen closely for these signals on the call: - Keytruda: Does management still describe the franchise as stable, even as the market starts focusing on the post-exclusivity horizon? - Newer launches: Are Winrevair and Lipfendra still being framed as real contributors rather than only future upside? - Animal Health and other businesses: Are they continuing to add breadth to the cash engine? - The margin bridge: Can management explain the Terns-related charges in a way that supports the view that they are front-loaded rather than structural?

If TERN-701 keeps advancing and the profit pressure fades faster than investors expect, the acquisition will look like a disciplined bridge. If core brands and newer launches start being cited as reasons for weaker profits, the narrative changes quickly from temporary accounting noise to a more durable margin reset.